Posted by Michael Wonder on 07 Mar 2021
Primary dyslipidaemia drug Praluent gets insurance benefit
5 March 2021 - Sanofi-Aventis Korea’s primary dyslipidaemia treatment Praluent (alirocumab) has won health insurance benefits, the government said.
On Friday, the Health Insurance Review and Assessment Service’s drug reimbursement review committee released the meeting's results on whether to grant insurance benefits to several medicines.
The review committee concluded that Praluent 75 mg and 100 mg solution in pre-filled pens for injection were valid for reimbursement.
